Floatz logo

Mart-1 Antigen

Non-melanomatous Skin Cancer

National Institutes of Health Clinical Center (CC)vaccinePhase 2Dormant
B
57/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
42/ 100
Competitive Position
95/ 100

Competitive context

40 Active assets in the Non-melanomatous Skin Cancer cohort.

Asset / SponsorPhaseRating
1-235-TUMOR NECROSIS FACTOR RECEPTOR (HUMAN) FUSION PROTEIN WITH 236-467-IMMUNOGLOBULIN G1 (HUMAN .GAMMA.1-CHAIN FC FRAGMENT), DIMER
University of Alabama at Birmingham
Phase 4BB
Pembrolizumab
Essen Biotech
Phase 2BB
Multiple Vitamins Injection
Women's College Hospital
Phase 3BB
gsk1120212
Cancer Research UK
Phase 2/3B
Multiple Vitamins Injection
Women's College Hospital
Phase 3B

View all 50 →

Same molecule, other indications

Mart-1 Antigen is also rated in:

cutaneous melanomaDormant
BB
Indicative ·
70 / 100
View asset →
uveal melanomaDormant
BB
Indicative ·
64 / 100
View asset →
melanomaDormant
BB
Indicative ·
64 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →